Guardant Health (NASDAQ:GH) Director Medina Manuel Hidalgo Sells 1,250 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,250 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $105.00, for a total value of $131,250.00. Following the completion of the transaction, the director directly owned 797 shares in the company, valued at $83,685. This represents a 61.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Friday, November 7th, Medina Manuel Hidalgo sold 1,500 shares of Guardant Health stock. The stock was sold at an average price of $95.19, for a total value of $142,785.00.
• On Friday, September 12th, Medina Manuel Hidalgo sold 2,165 shares of Guardant Health stock. The stock was sold at an average price of $54.16, for a total value of $117,256.40.

Guardant Health Stock Up 0.4%

Shares of NASDAQ GH opened at $103.60 on Thursday. Guardant Health, Inc. has a 12 month low of $29.91 and a 12 month high of $112.43. The company has a market cap of $13.06 billion, a price-to-earnings ratio of -32.42 and a beta of 1.58. The business has a fifty day simple moving average of $87.13 and a 200-day simple moving average of $64.63.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.09. During the same period last year, the company posted ($0.88) EPS. The company’s revenue was up 38.5% on a year-over-year basis. As a group, sell-side analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Driehaus Capital Management LLC acquired a new stake in shares of Guardant Health during the first quarter worth about $82,349,000. Alyeska Investment Group L.P. bought a new stake in Guardant Health during the 3rd quarter worth approximately $114,421,000. ARK Investment Management LLC raised its holdings in Guardant Health by 100.4% during the 2nd quarter. ARK Investment Management LLC now owns 2,823,497 shares of the company’s stock worth $146,935,000 after buying an additional 1,414,381 shares during the period. Invesco Ltd. raised its holdings in Guardant Health by 100.9% during the 1st quarter. Invesco Ltd. now owns 2,794,667 shares of the company’s stock worth $119,053,000 after buying an additional 1,403,670 shares during the period. Finally, Norges Bank bought a new position in Guardant Health in the second quarter valued at approximately $64,136,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GH has been the subject of a number of recent analyst reports. UBS Group raised their price objective on shares of Guardant Health from $80.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Leerink Partners increased their target price on Guardant Health from $70.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, September 25th. Piper Sandler raised their target price on Guardant Health from $60.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Barclays upped their price target on Guardant Health from $70.00 to $85.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. Finally, Evercore ISI increased their price objective on Guardant Health from $68.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $80.86.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.